(Breese et al. 1985a,b). For example, neonate-lesioned animals have increased locomotion following treatment with SKF-38393, a D 1 -DA receptor agonist, at doses that have minimal impact on control rats (Breese et al. 1985a,b). Repeated treatment with D 1 -DA agonists can lead to extremely high rates of activity in lesioned rats, and this "priming" effect can still be observed 6 months after the chronic drug treatment (Breese et al. 1985b;Criswell et al. 1989b). Supersensitivity of D 1 -DA receptors in neonatal-6-OHDA rats has also been linked to stereotyped responses and self-injurious behavior (SIB) following treatment with L-Dopa or apomorphine, suggesting that these animals can provide a valuable model for the self-injury and DA loss associated with Lesch-Nyhan disease (Breese et al. 1984a,b), a metabolic disorder primarily observed in male children (Lesch and Nyhan 1964).Paradoxically, although the aberrant responses in the neonate-lesioned rats can be completely blocked with selective D 1 -DA receptor antagonists (Breese et al. 1985a), these animals are remarkably subsensitive to haloperidol, even at doses which induce catalepsy in normal controls and in rats given 6-OHDA as young adults (Bruno et al. 1985;Duncan et al. 1987). Similarly, treatment with typical antipsychotic agents does not prevent the painful self-injury that occurs in LeschFrom the Departments of Psychiatry (SSM, DJK, GRB), Anesthesiology (GRB) and Pharmacology (GRB), Skipper Bowles Center For